Skip to content
Peptide research

Dermorphin

Also known as Dermorphone
Category
Muscle & Performance
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A frog-skin opioid peptide binding mu-opioid receptors at roughly 30 to 40 times morphine potency. Human evidence is limited to one small 1985 trial; longer-term safety data come mostly from animal and veterinary studies. It requires invasive spinal delivery to act centrally, carries risks of respiratory depression and dependence, and is already misused as a doping agent in horse racing. Not an approved human drug, with no legitimate research-grade supply.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Potent analgesia via mu-opioid receptor agonism

    Medium

    Animal assays found approximately 39–40 times morphine's potency; this is not a measured human potency ratio.

  • Prolonged postoperative pain relief (mean 43 hours from single intrathecal injection vs 34 hours for morphine)

    Medium

    Single 1985 randomized trial, never replicated, found significantly longer relief than morphine.

  • Reduced need for supplementary analgesics (only 22% of patients vs 58% for morphine, 88% for placebo)

    Medium

    Same 1985 trial; comparator was active pentazocine, not an inert placebo, never replicated.

Evidence limits

Evidence Level
Limited

A randomized postoperative clinical trial with active comparators (1985) demonstrated superior postoperative analgesia via intrathecal dermorphin versus intrathecal morphine and intramuscular pentazocine. Dermorphin provided 43-hour mean analgesia duration with 80% of patients needing no additional pain medication. No subsequent clinical trials have been conducted. Extensive preclinical data in rodents and horses confirm potent mu-opioid agonism. The 1985 clinical paper has received only ~15 citations, none from clinical researchers, representing a significant gap in translational development.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Opioid addiction or dependence

    Absolute

    Extremely potent mu-opioid agonist (30-40x morphine). High addiction potential.

  • Respiratory depression risk

    Absolute

    Potent opioid activity can cause life-threatening respiratory depression.

  • Concurrent opioid or sedative use

    Absolute

    Additive CNS depression risk. Can be fatal in combination.

Risk summary(10)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Nausea and vomiting — Reported in up to 50% of patients in open-label studies; reducible to <20% with domperidone pretreatment

    High
  • Urinary retention — 26% incidence in the 1985 clinical trial (comparable to morphine at 30%)

    Moderate
  • Respiratory depression — Expected class effect of potent mu-opioid agonists; not specifically quantified for dermorphin in humans but a theoretical concern given extreme potency

    Moderate
  • Tolerance and physical dependence — Demonstrated in animal models, though less pronounced than with morphine (65% vs 10% maintaining analgesia at 4 days continuous infusion)

    Moderate
  • Excitation and cardiovascular effects — Intravenous administration in horses caused acute excitation and increased heart rate (resolved within 5 minutes)

    Low
  • Cannot cross blood-brain barrier — Requires invasive intrathecal or intracerebroventricular administration, carrying inherent procedural risks (infection, headache, nerve damage)

    High
  • Endocrine disruption — Stimulates thyrotropin (TSH) secretion and decreases luteinizing hormone (LH) levels in humans

    Moderate
  • Abuse potential — High potency mu-opioid agonist with significant abuse liability; already misused in horse racing

    Moderate
  • Lack of safety data — Human evidence includes a 150-patient postoperative randomized trial and small endocrine studies; long-term safety remains unknown.

    High
  • Naloxone reversal eliminates analgesia — While naloxone reverses adverse effects, it simultaneously abolishes all analgesic benefit

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.